New York, NY -- (ReleaseWire) -- 02/01/2013 --Generex Biotechnology Corp. (OTCQB: GNBT) explained the potential of the technology platform used as the basis for its novel breast cancer immunotherapy product AE37.

The main potential advantage cancer immunotherapy like AE37 has compared to other cancer therapies is the ability to direct the body's immune system against targeted cancer cells, similar to other vaccines that direct the immune system against targeted infections.

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).

Find out more on GNBT here: http://www.wallstreetscoop.net/market-scan/?symbol=GNBT

Organovo Holdings, Inc. (OTCQX: ONVO) and the Knight Cancer Institute at Oregon Health & Science University (OHSU), have formed a collaboration to develop more clinically predictive in vitro three dimensional cancer models which will ultimately advance discovery of novel cancer therapeutics.

New biological models that more accurately replicate human cancer and malignant disease are desperately needed to enhance our understanding of how cancer develops and migrates and to deliver better oncology therapies for patients.

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in personalized cancer medicine.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications.

Find out where ONVO could be headed by getting the free full report here: http://www.wallstreetscoop.net/market-scan/?symbol=ONVO

About WallStreetScoop.net
WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

Contact Info:
Thomas Greene
Wall Street Scoop
info@wallstreetscoop.net
347-905-5009